Literature DB >> 20825985

Celiprolol therapy for vascular Ehlers-Danlos syndrome.

Benjamin S Brooke1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20825985     DOI： 10.1016/S0140-6736(10)61155-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Molecular diagnosis in vascular Ehlers-Danlos syndrome predicts pattern of arterial involvement and outcomes.

Authors:  Sherene Shalhub; James H Black; Alana C Cecchi; Zhi Xu; Ben F Griswold; Hazim J Safi; Dianna M Milewicz; Nazli B McDonnell
Journal:  J Vasc Surg       Date:  2014-03-18       Impact factor: 4.268

2.  Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome.

Authors:  Wilfried Briest; Timothy K Cooper; Hyun-Jin Tae; Melissa Krawczyk; Nazli B McDonnell; Mark I Talan
Journal:  J Pharmacol Exp Ther       Date:  2011-03-01       Impact factor: 4.030

3.  Celiprolol: A Unique Selective Adrenoceptor Modulator.

Authors:  James J Nawarskas; Angela Cheng-Lai; William H Frishman
Journal:  Cardiol Rev       Date:  2017 Sep/Oct       Impact factor: 2.644
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.